




BOSTON BIOMEDICAL RESEARCH INSTITUTE

ANNUAL REPORT 2000



THE BOSTON BIOMEDICAL RESEARCH INSTITUTE (BBRI) IS DEDICATED TO BASIC BIOMEDICAL RESEARCH TO PROMOTE THE UNDERSTANDING, TREATMENT AND PREVENTION OF SPECIFIC HUMAN DISEASES. THE AREAS OF INVESTIGATION CONCERN THE STRUCTURE AND FUNCTION OF MUSCLE PROTEINS, MECHANISMS OF CELL COMMUNICATION, AND THE CONTROL OF CELL GROWTH AND GENE FUNCTION. A MAJOR FOCUS IS MUSCLE CELL BIOLOGY WHICH HAS IMPLICATIONS FOR MUSCLE-RELATED DISEASES SUCH AS ASTHMA, STROKE, AND HEART FAILURE. WHEN APPROPRIATE, THE INSTITUTE COLLABORATES IN CLINICAL STUDIES OF PATIENTS TO APPLY THE RESULTS OF BASIC RESEARCH TO PROBLEMS OF HUMAN HEALTH AND THE CURE OF DISEASE. BBRI IS AN INDEPENDENT, NOT-FOR-PROFIT INSTITUTION.

MESSAGE FROM THE DIRECTOR

KATHLEEN G. MORGAN, PH.D.



We have arrived! As is documented in this Annual Report, over the last sixteen months we have chosen a new location for the Institute, sold our lease with SERI, issued BBRI bonds to finance the project, completely renovated an old cookie factory into a state-of-the-art research facility and moved our entire staff and equipment to 64 Grove Street in Watertown! The benefits of these changes will continue to emerge as time goes on, but we have clearly taken a giant step forward.

The move in 1962 of the Retina Foundation into the 20 Staniford Street building was four years of planning, construction and implementation. It is a marvelous testimony to the teamwork between our scientific and administrative staffs and our Board of Trustees and Corporators that our current relocation efforts were completed in less than half this time.

We have moved from 38,000 to 60,000 square feet of truly state-of-the-art space. The 20 Staniford Street building served us well, but after thirty-eight years, its infrastructure was definitely showing its age. It is a delight to now have epoxy lab benches and adequate ventilation for the X-Ray equipment in the crystallography facility—and to have air conditioning that can cope with 90°F temperatures outside!

Additionally, all investigators now have the opportunity to expand their own research programs and personnel in a way that was not possible in the old building. Many discussions are now going on regarding new opportunities for expanding our postdoctoral training programs, and hence the size of each laboratory's scientific staff. There are also ideas germinating regarding enhanced alliances and interactions with area graduate training programs. And, most encouragingly, we have the space to continue our aggressive faculty recruitment program that is a cornerstone of our strategic plan.

To ensure that we maximize the potential of this new facility, we aim to increase philanthropic support through a major fundraising effort, *A Campaign for BBRI: Intellectual Partners for the Future of Science*. It is very rewarding to see the generous support pledged so far in the leadership phase of the campaign - thank you!

During the last year, the search committee—chaired by Henry Paulus and including Phil Graceffa, Janet Smith, Michael Sherman and myself—has been successful in recruiting two outstanding young cancer biologists, Peter Erhardt and Steen Hansen, who are profiled in this report. They complement the efforts of Lynne Coluccio, Michael Sherman, Paul Leavis, and Andrew Bohm, bringing the Institute to critical mass in this research area, one of our three overlapping areas of scientific focus: motility, signal transduction and regulation of cell growth. The third focus area is much broader than just cancer biology, but it will be exciting over the coming years to see how these investigators use their special interest in the growth of cancer cells to capitalize on the fundamental discoveries being made at the Institute.

We have incorporated into the design of the building elements that reflect and enhance the collaborative, collegial environment that has always characterized the Institute. Our "open lab design" continues the longtime tradition of BBRI to have as few walls as possible between laboratory areas. This design greatly facilitates access to shared scientific equipment and promotes the free flow of ideas across theoretical laboratory boundaries. The new building also has a number of small conference rooms for small group meetings and "media/coffee" centers for informal discussions.

Now that BBRI "owns its own home" there is a tangibly stronger sense of identity for the Institute. We have had an outstanding research seminar program this year (organized by Roberto Dominguez) and many of our outside speakers have marveled at the quality of scientific activity and interaction at the new Institute.

As always, I invite any of you to visit our new home and tour the new laboratories.

MESSAGE FROM THE PRESIDENT

DAVID A. GIBBS, SC.D.



It has been another very productive and successful year at BBRI - we have made an historic move into our own research home in Watertown!

It was in mid-1998 that the outline of a tremendous opportunity started to take shape as we negotiated the sale of our remaining lease at 20 Staniford Street to the Schepens Eye Research Institute (SERI). It was not until mid-October 1998 that an agreement was signed for the sale of our lease to SERI for \$8.4 million, with the understanding that we would vacate the premises by the end of February 2000.

During the negotiations with SERI, the officers and faculty of BBRI began searching for a site. By August 1998 we had focused on 64 Grove Street in Watertown, a rather dilapidated 100,000 sq. ft. factory building which once housed the Golden Cookie Bakery! To our eye the building offered adequate space, high ceilings through which we could run the infrastructure necessary for modern scientific equipment, and . . . location, location, location. We are still just a short distance from all of the Boston and Cambridge academic centers with whom our scientists interact and collaborate.

To finance the project on such short notice, we could not conduct a traditional major fundraising campaign, so we needed to secure alternative financing. A joint Board/faculty construction finance committee oversaw the research, negotiation and sale of \$17 million in tax-exempt bonds in February 1999 at the rate of 5.75%. For this sale we received an investment grade rating from both Moody's and Standard & Poor's. Another joint Board/faculty committee focused on the construction of the new facility. DTS Shaw Architects and Siena Construction Co. were selected for their experience in designing and constructing research facilities and their commitment to our deadline.

In mid-January 1999 we purchased 64 Grove Street and through the excellent cooperation of the Town of Watertown, received building permits and variances. Effectively, we had twelve months remaining to build the facility and move in. Not unexpectedly, many unforeseen complications were overcome during the demolition of part of the building and securing the infrastructure of the existing building.


The fact that we located, financed, built and moved into the new facility within sixteen months is quite remarkable. It is an achievement underpinned by the "cooperativity" throughout the BBRI family, which I referred to in last year's report, and a tremendous amount of hard work to complete major tasks against very tight deadlines!! Much has been achieved, but there remains so much more to be done. We have a superb new research home that offers outstanding opportunities for our existing research programs to flourish and new research programs to begin, but to do this we must raise the level of philanthropic support for BBRI through our current fund drive, *A Campaign for BBRI: Intellectual Partners for the Future of Science*.

I urge each and every one of you to come and take a private tour of our new facility and to respond as generously as possible to our largest fundraising effort ever at BBRI!

THE ROAD TO GROVE STREET



BBRI'S NEW RESEARCH HOME AT 64 GROVE STREET IN WATERTOWN.

20 STANIFORD STREET, BOSTON: BBRI'S HOME FROM ITS FOUNDED IN 1968 UNTIL FEBRUARY 2000.




A LABORATORY AT STANIFORD STREET. THE INSTITUTE'S GREAT NEED FOR ADDITIONAL SPACE AND MODERNIZED LABORATORIES PROMPTED THE RELOCATION.

THE STATE-OF-THE-ART LABORATORIES AT BBRI'S NEW 60,000 SQ. FT. FACILITY ENCOURAGE COLLABORATION THROUGH AN 'OPEN LAB' LAYOUT AND SHARED EQUIPMENT FACILITIES. BBRI INCORPORATED 'FUTURE LAB' SPACE INTO THE BUILDING DESIGN TO ACCOMMODATE ONGOING GROWTH.



THE MAKING OF A

BEFORE: APRIL 5, 1999. A VIEW OF THE NORTH SIDE OF 64 GROVE STREET JUST BEFORE THE DEMOLITION BEGAN. IN TEN MONTHS, BBRI TRANSFORMED THIS OLD FACTORY BUILDING THAT ONCE HOUSED WATERTOWN'S LEGENDARY GOLDEN COOKIE BAKERY INTO A STATE-OF-THE-ART SCIENTIFIC RESEARCH FACILITY. A SERIES OF CHIMNEYS FROM THE OLD COOKIE OVENS ARE VISIBLE ALONG THIS NORTH-FACING WALL.



APRIL 16, 1999. AFTER THE GOLDEN COOKIE BAKERY'S DEMISE, 64 GROVE STREET MOST RECENTLY HOUSED A FURNITURE FACTORY. HERE, DESTRUCTION OF THE FACTORY SHOWROOMS MAKES WAY FOR CONSTRUCTION OF NEW LABORATORIES ON THE BUILDING'S SECOND FLOOR.



MAY 28, 1999. DEMOLITION IS UNDERWAY. 40,000 OF THE BUILDING'S 100,000 ORIGINAL SQUARE FOOTAGE WERE DEMOLISHED TO CREATE A 65-SPACE PARKING LOT FOR BBRI'S STAFF AND VISITORS.



OCTOBER 1, 1999. RECONSTRUCTION OF THE THIRD FLOOR WALL ABOVE THE GROVE STREET ENTRANCE.



FROM BOSTON TO WATERTOWN . . .

OCTOBER 15, 1998
BBRI AGREES TO SELL ITS
LEASEHOLD AT 20 STANFORD
STREET TO THE SCHEPENS EYE
RESEARCH INSTITUTE



FEBRUARY 1, 1999
BBRI SUCCESSFULLY SELLS \$17
MILLION IN TAX-EXEMPT BONDS



MAY 14, 1999
GROUNDBREAKING
CEREMONY AT 64 GROVE
STREET



JANUARY 16, 1999
PURCHASE OF THE GROVE
STREET PROPERTY




APRIL 1999
DEMOLITION BEGINS

LABORATORY

FEBRUARY 12, 2000. NEARING COMPLETION: A VIEW OF THE THIRD FLOOR LABORATORIES LOOKING EAST, FOUR DAYS BEFORE BBRI'S SCHEDULED MOVE FROM STANIFORD STREET.



BBRI'S LIBRARY, WHICH OFFERS THE STAFF ON-LINE ACCESS TO SCIENTIFIC JOURNALS, MICROFILM ARCHIVES AND A QUIET PLACE FOR RESEARCH AND WRITING.



MAY 15, 2000. THE DAY BEFORE THE GRAND OPENING. BRUSHED STEEL AND LIGHT OAK ACCENT THE ANGULAR SHAPE OF BBRI'S NEW LOBBY DESIGN BY DTS SHAW ARCHITECTS, MEANT TO PROVIDE A LINK BETWEEN THE BUILDING'S PAST AND THE FUTURE.



AFTER: SEPTEMBER 2000. THE FINISHED PRODUCT: A VIEW OF THE COMPLETED BUILDING'S NORTH SIDE.



BUILDING A SCIENTIFIC INSTITUTE

JUNE 1999
CONSTRUCTION BEGINS WITH REINFORCEMENT OF BUILDINGS, STEEL BEAMS, PILLARS AND FOUNDATION



DECEMBER 1999
CLOSURE OF BUILDING - ROOF AND WINDOWS INSTALLED, POWER AND HEAT IN PLACE



JANUARY-FEBRUARY 2000
INTERIOR CONSTRUCTION COMPLETED




FEBRUARY 16-28, 2000
BBRI MOVES INTO ITS NEW HOME IN WATERTOWN



MAY 16, 2000
BBRI CELEBRATES GRAND OPENING WITH 230 FRIENDS AND SUPPORTERS

TWO NEW SCIENTISTS JOIN BBRI FACULTY

DR. PETER ERHARDT AND DR. STEEN HANSEN, BOTH M.D.-PH.D.S, WERE RECENTLY APPOINTED AS MEMBERS OF THE FACULTY AT BBRI. WITH EXPERTISE IN SIGNAL TRANSDUCTION AND CELL GROWTH, THE NEW SCIENTISTS' RESEARCH INTERESTS FIT WELL INTO THE INSTITUTE'S THREE OVERLAPPING AREAS OF STUDY—MOTILITY, SIGNAL TRANSDUCTION, AND REGULATION OF CELL GROWTH. THEY JOIN DRs. MICHAEL SHERMAN, PAUL LEAVIS, LYNNE COLUCCIO AND ANDREW BOHM IN A GROWING GROUP OF CANCER BIOLOGISTS AT BBRI.



STEEN H. HANSEN,
M.D., D.M.SC. (PH.D.)

Dr. Steen Hansen comes to BBRI from a postdoctoral fellowship at the University of San Francisco Cancer Research Center. He received his M.D. and Ph.D. from University of Copenhagen, where he also completed his medical internship. Steen also had been a postdoctoral fellow in the Department of Pediatrics at Mass. General Hospital, Harvard University and was a recipient of the prestigious Weimann Foundation Senior Research Fellowship.

Steen's research focuses on understanding the series of events that cause normal epithelial cells to mutate into malignant cells. Most of our internal organs are made up of polarized epithelial cells, which can undergo mutations to give rise to malignant tumors called adenocarcinomas. More than 80% of lethal cancers that afflict humans are adenocarcinomas. Among these are colon and pancreatic cancers, of which up to 70% are associated with mutations in a signaling protein called Ras. Specifically, Steen is investigating the mechanisms by which Ras transmits signals that cause changes in the behavior of polarized epithelial cells that mimic alterations that occur in early stages of adenocarcinomas. As a postdoctoral fellow, Steen discovered that Ras activation results in the induction of another signaling protein, Rnd3, which may play a role in the transformation of normal epithelial cells to adenocarcinomas. Such knowledge is important, as it is likely to identify possible cellular targets for early diagnosis and therapeutic intervention of malignant tumors.

PETER ERHARDT, M.D., PH.D.

Dr. Peter Erhardt completed his postdoctoral training in the Department of Molecular Genetics at Dana-Farber Cancer Institute, Harvard Medical School, where he published ten papers in highly recognized journals, and comes to BBRI from a transitional research assistant professorship at Boston University. He received his M.D. and Ph.D. from the Medical School of Pecs in Hungary, where he also completed his medical residencies.



Peter is a signal transduction expert with research interests in programmed cell death, or apoptosis. Specifically, his research focuses on the mechanism of apoptosis and how growth factors prevent cell death by activating survival pathways. Apoptosis is a highly regulated process that eliminates unwanted cells during development as well as cells damaged by external factors. The death of cells by apoptosis is thought to contribute to the disease of heart failure. Conversely, suppression of apoptosis contributes to the uncontrolled growth of cancer cells. Peter is studying the role of certain proteins that either block or modulate apoptosis. For example, he has discovered that the protein B-Raf kinase plays an important role in blocking cell death at a late stage of apoptosis. This discovery may provide a unique opportunity for treating diseases associated with apoptotic cell death, such as cardiac ischemia. Peter is pursuing a new technique for studying B-Raf that may lead to the development of new therapies for ischemic heart disease. A second project involves the study of the protein MDM2 and its role as an inhibitor of the tumor suppressor p53, in an effort to seek new therapies useful in the treatment of certain cancers.

DEVELOPMENT REPORT

ALLIE BLODGETT



Momentum is building in the development effort at BBRI after a very productive year of fundraising. Through the generosity of our supporters and the dedicated work of the Development Committee and the Development Office, we succeeded in reaching our Annual Fund goal of \$425,000. We're happy to report that the average gift to this year's drive increased by 10%. This wonderful support, totaling \$428,000, is invaluable to the ongoing success of BBRI's basic research programs.

With sound guidance from the Public Relations Committee, on May 16th BBRI's development team orchestrated a very successful Grand Opening Celebration at the Institute's new research home in Watertown. Over 230 friends and supporters joined us for this very special evening, including leaders from the local community, and many friends new to the Institute. The highlight of the evening was a keynote address from renowned cancer researcher, Dr. Judah Folkman of Children's Hospital and Harvard Medical School.

Last year at this time, we were in the planning stages of BBRI's first major capital fund drive. Today, this effort is making good progress with significant leadership support from close friends and importantly, some new friends. A *Campaign for BBRI: Intellectual Partners for the Future of Science* is our most ambitious fundraising effort to date. It is a comprehensive campaign that aims to enlarge BBRI's scientific staff, expand the postdoctoral fellows program, form a Pilot Fund for innovative scientific projects, and provide resources for scientific equipment, unfinished lab space and educational outreach programs for local students.

A *Campaign for BBRI: Intellectual Partners for the Future of Science* takes its name from remarks made by BBRI's founder, Dr. Endre Balazs, at the 1999 Annual Meeting. In his address, Dr. Balazs urged us to join scientists in the effort to communicate to a wider public the fast-paced discoveries that are continually taking place in the scientific field. As he said that evening:

"People ask me, 'Why should I support basic science?' I believe you should support it because you are in an intellectual relationship. You want to know more about the human body, health and disease, and that's what your contribution is: creating and maintaining this partnership, this intellectual partnership. We need you, because you are our contact with the lay public around us, the bankers, the businessmen, the lawyers and people in this room. On this partnership we'll build the funds that we need."

I'd like to take this opportunity to personally thank all of you for helping make my four years as Chair of the Development Committee a valuable and enjoyable experience. I will pass the responsibility of Development Chair to Jake Layton, one of the most personable, intelligent and committed young men I've been fortunate enough to work with. My next task will be to seek new friends for the Institute. Together Jake and I have ambitious goals for the future growth of BBRI.

Many thanks to our Trustees, Corporators, and all of you for recognizing the importance of basic research to human health and the cure of disease. Finally, my very special thanks to members of the Development Committee: Tony Cabot, David Crockett, Jillian Darling, Tom Eddy, Greg Getschow, David Gibbs, Charlie Ives, Pat Jackson, Jake Layton, Kathleen Morgan, Henry Paulus, Janie Stephenson, Ginny Sullivan, Bill Tyler and Simon Welsby.

DONORS

FOUNDATIONS, BUSINESSES AND INDIVIDUALS WHO GENEROUSLY
GAVE US THEIR SUPPORT AND ENCOURAGEMENT. FISCAL 2000

FOUNDATIONS & BUSINESSES

ANONYMOUS
ANONYMOUS
APPLE LANE FOUNDATION
BANKBOSTON
BINGHAM DANA LLP
BIOGEN
BLOUT FAMILY FOUNDATION
COMPAG
THE HOWARD C. CONNOR CHARITABLE FOUNDATION
T. R. DIBENEDETTO FOUNDATION
HENDERSON FOUNDATION
HURDLE HILL FOUNDATION
LYNN JACHNEY CHARTERS, INC.
THE KENWOOD FOUNDATION
MARSH USA, INC.
THE MILLIPORE FOUNDATION
NEW ENGLAND BIOLABS, INC.
GEOFFREY & CLARE NUNES CHARITABLE TRUST
G. GORHAM PETERS TRUST
THE HAROLD WHITWORTH PIERCE CHARITABLE TRUST
PROSPECTUS, INC.
PUTNAM FURNITURE LEASING COMPANY, INC.
QUIN, RICHARD & VECCHI, P.C.
FRED M. RODDY FOUNDATION, INC.
SHOLLEY FOUNDATION, INC.

STATE STREET CORPORATION
TAMARACK FOUNDATION
TAPLIN CHARITABLE LEAD TRUST
THE THORACIC FOUNDATION
VICAM LIMITED PARTNERSHIP

DONORS TO ANNUAL FUND

EXPLORER

ANONYMOUS
MR. & MRS. ERNEST HENDERSON, III
THE THORACIC FOUNDATION

BENEFACTOR

DR. PETER S. COLEMAN
DR. DONALD G. COMB
THE HAROLD WHITWORTH PIERCE CHARITABLE TRUST
THE MILLIPORE FOUNDATION


PATRON

ANONYMOUS
ANONYMOUS

FROM LEFT: ANNGIE TYLER, CHRISTOPHER ROGERS, AND BBRI
OVERSEER WILLIAM TYLER AT BBRI'S GRAND OPENING CELEBRATION
IN MAY.



DONORS



TOP-FROM LEFT: BBRI PRESIDENT DR. DAVID GIBBS, BBRI CHAIR MR. JOHN B. FRENCH, KEYNOTE SPEAKER DR. JUDAH FOLKMAN, TRUSTEE DR. ELKAN BLOUT, AND BBRI DIRECTOR DR. KATHLEEN MORGAN AT THE GRAND OPENING.

MIDDLE-FROM LEFT: TRUSTEES GEOFF NUNES AND ALLIE BLODGETT WITH CAROLE BENNING.

BOTTOM-FROM LEFT: MR. GEORGE BUCKLEY, SCIENCE CURRICULUM COORDINATOR FOR WATERTOWN PUBLIC SCHOOLS, OBSERVES A DEMONSTRATION IN DR. ANDREW BOHM'S LABORATORY AT THE GRAND OPENING.



PATRON, CONT'D

ANDRE BALAZS
DR. ENDRE A. BALAZS
MR. & MRS. THOMAS P. EDDY
G. GORHAM PETERS TRUST
MR. & MRS. JUSTIN P. MORREALE
JOHN A. SHANE
GARY SHAW, AIA

SPONSOR

BANKBOSTON
THOMAS R. & LINDA DIBENEDETTO
THE HOWARD C. CONNOR
CHARITABLE FOUNDATION
LYNN JACHNEY
MRS. GRETA B. LAYTON
MR. PETER B. SHOLLEY
JANE H. STEPHENSON

SUPPORTER

ALLIE & DON BLODGETT
GAIL & ELKAN BLOUT
CHILTON S. CABOT
DR. & MRS. JOHN F. CODINGTON
MR. & MRS. FREDERIC CORNEEL
JOHN & DEBORAH FRENCH
DR. JOHN & MRS. NORA GERGELY



DONORS

SUPPORTER, CONT'D


DR. & MRS. DAVID A. GIBBS
NATHANIEL HOWE
CHARLES C. IVES, II
MR. & MRS. JOHN R. LAYTON
ELI & ANNE W. MANCHESTER
DR. KATHLEEN G. MORGAN
CLARE & GEOFFREY NUNES
DR. HENRY PAULUS
FRED M. RODDY FOUNDATION, INC.
MR. & MRS. WILLIAM B. TYLER

ASSOCIATE

MR. & MRS. CARL F. BARRON
ROBERT P. BONDARYK, PH.D.
LILLIAN M. CLANCY
NANCY E. CONCANNON
LESLIE R. CONEY, PH.D.
MR. & MRS. WILLIAM H. CONGLETON
WILLIAM E. CRESS & DANIEL V. CALANO, JR.
DAVID C. CROCKETT
MRS. EDITH L. DABNEY
MR. & MRS. NELSON J. DARLING, JR.
TOM & JILLIAN DARLING
DR. PETER F. DAIVSON
DAVID C. DE SIEYES
WILLIAM ELPERS
EDWARD G. FEY, PH.D.
JACKIE FINDLAY
MR. & MRS. ALBERT M. FORTIER, JR.
RONALD GARMAY
GREGORY S. GETSCHOW
ROBERT GOTTLIEB & MARGO ROSENBAACH
ELLEN W. GRIGGS
MARTHA N. JONES
R. WILLIS & BARBARA B. LEITH
MR. & MRS. JOHN LOWELL
WILLIAM & ANGELA LOWELL
MRS. NATHANIEL C. NASH
MARY ALICE NICHOLS
MR. & MRS. RICHARD D. PHIPPEN
CHARLES E. PROCKNOW
QUIN, RICHARD & VECCHI, P.C.
VINCENT F. & THERESA M. RASO
D. RAO SANADI, PH.D.
WILLIAM SARTORELLI
GILBERT L. STEWARD, JR.
MR. & MRS. GALEN L. STONE
MR. & MRS. JOHN F. TAPLIN
MR. & MRS. EUSTIS WALCOTT
DANA & RONNA WOODWARD

FRIEND

MR. & MRS. GARRETT D. BOWNE
MR. & MRS. F. GORHAM BRIGHAM, JR.
PENELOPE STOHN BROUWER
ROBERT BURROWS
KENT COIT & GAIL MAZZARA
DR. ROBERTO CREA



FROM LEFT: ALISON CONNOLLY OF THE BOSTON BUSINESS JOURNAL, TRUSTEE TONY CABOT, MARY ANN CABOT, AND BBRI CAMPAIGN MANAGER VIRGINIA SULLIVAN AT A DEMONSTRATION IN DR. SHERWIN LEHRER'S LABORATORY AT THE GRAND OPENING.

TARRANT CUTLER
GRANTON H. DOWSE, JR.
MRS. C. CONWAY FELTON
HOLLIS FRENCH, II
MS. VIVIAN WENHUAY CHEN HUANG
MARY ELIOT JACKSON
CAROL & SUMNER KAUFMAN
DR. BARB ARIEL KOHN
THOMAS E. LEGGAT
MISS SUSAN G. LORING
JANET MACLEAN
MARILYN & HARRY MARGULIUS
WILLIAM R. PAGE
MS. LOUISE A. PFEIFFER
DANIEL PHILLIPS (IN HONOR OF JAKE LAYTON)
GLADYS H. POOR
RACHEL & JOEL RECK
MRS. MERION M. RITTER
DRS. NILIMA & SATYAPRIYA SARKAR
CHESTER M. SAWTELLE
MR. & MRS. ROSS SHERBROOKE
MR. REGINALD H. SMITHWICK
MR. & MRS. RICHARD D. STONE
MR. & MRS. HARRY SYRIGOS
JOHN VECCHI
MONTE J. WALLACE
CONSTANCE V. R. WHITE

MATCHING GIFTS

BANK BOSTON
COMPAG
STATE STREET CORPORATION

THE BOARD OF TRUSTEES

CORPORATION MEMBERS, SCIENTIFIC ADVISORY COMMITTEE AND STANDING COMMITTEES

THE BOARD OF TRUSTEES

OFFICERS

JOHN B. FRENCH, CHAIR
DAVID A. GIBBS, SC.D., PRESIDENT
ALLIE FLATHER BLODGETT, VICE PRESIDENT
CHARLES C. IVES, II, VICE PRESIDENT
W. LYNN JACHNEY, VICE PRESIDENT
ERNEST HENDERSON, III, TREASURER
JOHN R. LAYTON, SECRETARY-CLERK
KATHLEEN G. MORGAN, PH.D., DIRECTOR
HENRY PAULUS, PH.D., DEPUTY DIRECTOR

TRUSTEES

ELKAN R. BLOUT, PH.D.
CHILTON S. CABOT
DONALD G. COMB, PH.D.
THOMAS R. DIBENEDETTO
NATHANIEL S. HOWE, JR.
HARRY JOHNSON
WILLIAM A. LOWELL
GEOFFREY NUNES
JOHN A. SHANE
JANE H. STEPHENSON

OVERSEERS

DAVID C. CROCKETT
JOHN GERGELY, M.D., PH.D., D.SC.M.
(HON.)
JOHN F. TAPLIN
WILLIAM B. TYLER

CORPORATION MEMBERS

ANDRE BALAZS
ENDRE A. BALAZS, M.D.
ROBERT P. BONDARYK, PH.D.
PENELOPE STOHN BROUWER
DANIEL V. CALAND, JR.
LILLIAN M. CLANCY
KENT A. COIT
NANCY E. CONCANNON
LESLIE R. CONEY, PH.D.
FREDERIC G. CORNEEL
ROBERTO CREA, PH.D.
WILLIAM E. CRESS
JILLIAN HOSFORD DARLING
THOMAS W. DARLING
PETER F. DAVISON, PH.D.
JANET L. DENLINGER, PH.D.
DAVID C. DE SIEYES
MEG DOUGLAS-HAMILTON
THOMAS P. EDDY
EDWARD G. FEY, PH.D.
ALBERT M. FORTIER, JR.
RONALD GARMEY
GREGORY S. GETSCHOW
ROBERT M. GOTTLIEB
ELLEN W. GRIGGS
MARY LOUISE HENDERSON
VIVIAN WENHUEY CHEN HUANG

MARY ELIOT JACKSON
DENHOLM M. JACOBS
JACK T. JOHANSEN, PH.D.
EDWARD C. JOHNSON, 3D
MARTHA N. JONES
EDWIN M. KANIA
RONALD W. LENNOX, PH.D.
ELI MANCHESTER, JR.
CORNELIUS J. MCCARTHY
ALICE MCCARTHY
JUSTIN P. MORREALE
MRS. NATHANIEL C. NASH
MRS. RICHARD D. PHIPPEN
CHARLES E. PROCKNOW
VINCENT F. RASO, C.P.A.
D. RAO SANADI, PH.D.
WILLIAM A. SARTORELLI
PETER B. SHOLLEY
GILBERT L. STEWARD, JR.
ANNE B. STONE
GALEN L. STONE
NORMAN R. VEENSTRA
EUSTIS WALCOTT
RONNA G. WOODWARD

SCIENTIFIC ADVISORY COMMITTEE

NORTON B. GILULA, PH.D.
MARTIN HASLANGER, PH.D.
CHARLES C. RICHARDSON, M.D.
THOMAS P. STOSSEL, M.D.
JEAN-PIERRE WERY, PH.D.

COMMITTEES OF THE BOARD

BUDGET AND FINANCE COMMITTEE

JOHN R. LAYTON, CHAIR
PETER F. DAVISON, PH.D.
DAVID A. GIBBS, SC.D.
THOMAS J. MCQUAID, C.P.A.
KATHLEEN G. MORGAN, PH.D.
GEOFFREY NUNES
VINCENT F. RASO, C.P.A.

DEVELOPMENT COMMITTEE

ALLIE FLATHER BLODGETT, CHAIR
CHILTON S. CABOT
DAVID C. CROCKETT
JILLIAN HOSFORD DARLING
THOMAS P. EDDY
GREGORY S. GETSCHOW
DAVID A. GIBBS, SC.D.
CHARLES C. IVES, II
MARY ELIOT JACKSON
KATHLEEN G. MORGAN, PH.D.
HENRY PAULUS, PH.D.
JANE H. STEPHENSON
VIRGINIA SULLIVAN

WILLIAM B. TYLER
SIMON D. J. WELSBY

GOVERNANCE COMMITTEE

W. LYNN JACHNEY, CHAIR
ALLIE FLATHER BLODGETT
JOHN B. FRENCH
DAVID A. GIBBS, SC.D.
ERNEST HENDERSON, III
HARRY JOHNSON
JOHN R. LAYTON
KATHLEEN G. MORGAN, PH.D.
HENRY PAULUS, PH.D.
JOHN A. SHANE

INVESTMENT COMMITTEE

ERNEST HENDERSON, III, CHAIR
ELKAN R. BLOUT, PH.D.
CHILTON S. CABOT
THOMAS R. DIBENEDETTO
DAVID A. GIBBS, SC.D.
THOMAS J. MCQUAID, C.P.A.
KATHLEEN G. MORGAN, PH.D.
HENRY PAULUS, PH.D.
VINCENT F. RASO, C.P.A.

NOMINATING COMMITTEE

WILLIAM B. TYLER, CHAIR
ALLIE FLATHER BLODGETT
JOHN GERGELY, M.D., PH.D., D.SC.M.
(HON.)
DAVID A. GIBBS, SC.D.
WILLIAM A. LOWELL
KATHLEEN G. MORGAN, PH.D.
SIMON D. J. WELSBY

PATENTS & TECHNOLOGY TRANSFER COMMITTEE

ROBERT P. BONDARYK, PH.D., CO-CHAIR
EDWARD G. FEY, PH.D., CO-CHAIR
ELKAN R. BLOUT, PH.D.
JILLIAN HOSFORD DARLING
DAVID A. GIBBS, SC.D.
NATHANIEL S. HOWE, JR.
KATHLEEN G. MORGAN, PH.D.
HENRY PAULUS, PH.D.
JOHN F. TAPLIN
PAMELA A. TORPEY

PUBLIC RELATIONS COMMITTEE

HARRY JOHNSON, CHAIR
LYNNE COLUCCIO, PH.D.
DAVID C. DE SIEYES
DAVID A. GIBBS, SC.D.
MARY LOUISE HENDERSON
MARTHA N. JONES
KATHLEEN G. MORGAN, PH.D.
JANE H. STEPHENSON
ANNE B. STONE
SIMON D. J. WELSBY
RONNA G. WOODWARD

TREASURER'S REPORT

ERNEST HENDERSON, III



As noted in both the Messages from the Director and the President, BBRI moved into its brand new state-of-the-art research facility located in Watertown, Massachusetts during February 2000. The total cost of the project was \$16,600,000. This included \$550,000 for the acquisition of land, \$15,600,000 for construction of the building, \$150,000 for the purchase of new furniture, and \$367,000 in capitalized interest cost. These figures are reflected in the property and equipment and capitalized interest portions of the statements of financial position.

After five years as Chief Financial Officer, Thomas McQuaid left BBRI in August 2000 to take a position at the Forsyth Dental Center. On behalf of the Trustees, I would like to thank Tom for his outstanding contributions to the Institute. BBRI is fortunate to have recruited Alan Kaye as our new CFO. Alan holds a Masters in Business Administration in Finance and is a Certified Public Accountant. He has eighteen years experience in financial management, most recently as the Controller at The Schepens Eye Research Institute. We welcome Alan to BBRI.

Investments topped \$18,000,000 at June 30, 2000, an increase of \$5.3 million over the prior year. This increase reflects receipt of the final \$4.8 million from the sale of our leaseholds in Boston and Townsend to The Schepens Eye Research Institute. The remainder of the increase is due to net investment appreciation on the BBRI portfolio.

During the fiscal year the Institute was awarded nine new grants from the National Institutes of Health and the National Science Foundation. Additionally, the Institute received grants from the American Heart Association, the March of Dimes, the Hereditary Disease Foundation, and the Medical Foundation - Charles A. King Trust.

A review of financial results indicates that total unrestricted support of approximately \$9,207,000 grew 20% over the prior year. Revenue from federal agencies represents approximately 87% of revenue from grants and contracts.

Total expenses of \$8,916,000 increased approximately \$1,500,000 over the prior year due primarily to research initiatives, facility related personnel and operating costs. In addition to plant personnel, BBRI now maintains its own in vivo facility, glass washers and library.

Philanthropic giving grew significantly as BBRI has entered the early stages of its Comprehensive Campaign. Fiscal year 2000 contributions of approximately \$784,000 represent an increase of almost 78% over the prior year. This effort would not be possible without the tireless efforts of Allie Blodgett and the Development Committee. With the new facility, BBRI has positioned itself to meet the growing needs of its scientific community. Our greatest ongoing challenge is the expansion of our "intellectual capital." New recruits, expansion of existing programs, the nearly doubling of our space, and the inception of a pilot program to promote new ideas do not come inexpensively. We invite you to increase your participation, expand our circle of friends and supporters and help us take advantage of our exciting new opportunities!

GRANTS AND FELLOWSHIP AWARDS

RESEARCH GRANTS

NATIONAL INSTITUTES OF HEALTH

DR. BADWEY	MAPK IN THE CONTRACTILE PHENOTYPE OF SMOOTH MUSCLE	3/96-2/01	\$1,128,000
DR. BADWEY	ENZYMES MODULATING SECOND MESSENGERS IN NEUTROPHILS	8/98-7/03	1,096,000
DR. BOHM	FUNCTIONAL STUDIES OF THE YEAST POLY (A) POLYMERASE	9/99-8/01	47,000*
DR. BOHM	CATALYTIC MECHANISM AND REGULATION OF MAMMALIAN ADENYLYL CYCLASE	9/99-8/01	50,000*
DR. COLUCCIO	MYOSIN-I MEDIATED PROCESSES IN LIVER CELLS	8/97-7/01	1,407,000
DR. DOMINGUEZ	ATOMIC STRUCTURE OF SMOOTH MUSCLE CALDESMON	3/00-2/05	1,620,000*
DR. HARRISON	STRUCTURE / FUNCTION ANALYSIS OF MOLECULAR CHAPERONES	7/98-6/03	1,206,000
DR. IKEMOTO	STRUCTURE AND FUNCTION OF SARCOPLASMIC RETICULUM	9/96-8/01	2,416,000
DR. LEHRER	TROPOMYOSIN AND MYOSIN INTERACTION IN MUSCLE	12/95-11/00	2,044,000
DR. MORGAN	REGULATION OF CONTRACTION AND GROWTH OF BLOOD VESSELS	3/00-2/04	1,316,000*
DR. MORGAN	CONTRACTION OF VASCULAR SMOOTH MUSCLE CELLS	4/97-3/01	768,000
DR. MORGAN	CONFOCAL MICROSCOPE FACILITY	4/00-3/01	293,000*
DR. PAULUS	MECHANISM OF PROTEIN SPLICING IN MYCOBACTERIUM	4/97-3/01	1,403,000
DR. RASO	A BINARY SYSTEM FOR CELL-TARGETED DELIVERY	3/99-2/01	246,000
DR. RASO	VACCINE TO ELICIT CATALYTIC ANTI-COCAINE ANTIBODIES	4/99-3/02	471,000
DR. SARKAR	FUNCTION OF POLYADENYLATE SEQUENCES IN BACTERIAL RNA	9/98-8/02	1,419,000
DR. SHERMAN	MOLECULAR CHAPERONES AND PROTEIN PHOSPHORYLATION	5/96-4/01	1,081,000
DR. SHERMAN	HSP72 AND REGULATION OF STRESS-KINASES IN TUMOR CELLS	5/00-4/05	1,991,000*
DR. TAO (MERIT)	PROXIMITY RELATIONSHIP AMONG MUSCLE PROTEINS	5/96-3/01	2,201,000
DR. TAO	MOLECULAR INTERACTIONS OF THE MYOSIN PHOSPHATES SUBUNITS	2/00-1/04	1,282,000*
DR. TOKER	PHOSPHOINOSITIDE 3-KINASE C SIGNALING	12/98-11/03	1,385,000
DR. TOKER	PHOSPHOLIPASE C SIGNALING IN INTEGRIN MEDIATED CARCINOMA	8/99-7/01	275,000*
DR. WANG (PRO. PROJ.)	MOLECULAR MECHANISM OF SMOOTH MUSCLE REGULATION	12/97-11/02	7,696,000
DR. WOHLRAB	PHOSPHATE PATH WITHIN HOMODIMERIC MITOCHONDRIAL PTP	5/98-4/02	1,412,000

NATIONAL SCIENCE FOUNDATION

DR. ERHARDT	MECHANISM OF CELL SURVIVAL MEDIATED BY THE B-RAF KINASE	6/00-5/03	309,000*
-------------	---	-----------	----------

AMERICAN CANCER SOCIETY

DR. BOHM	STRUCTURE OF G-BETA GAMMA / EFFECTOR COMPLEX	1/99-12/01	342,000
----------	--	------------	---------

AMERICAN HEART ASSOCIATION

DR. DOMINGUEZ	X-RAY CRYSTAL STUDY OF RECOMBITANT HUMAN CALCYCLIN AND ITS COMPLEX WITH A TARGET SMOOTH MUSCLE CALDESMON FRAGMENT	7/99-6/01	77,000*
DR. EL-HAYEK CONRAD	STRUCTURAL FUNCTIONAL DOMAIN MAPPING OF THE CARDIAC JFP	1/00-12/03	260,000*
DR. LEAVIS	DEVELOPMENT OF ANTIBODIES AGAINST PREIMPLANTATION FACTOR & INVESTIGATION CONTRACEPTIVE POTENTIAL	10/98-9/99	58,400

DEFENSE ADVANCED RESEARCH PROJECTS AGENCY

DR. LEAVIS	EMBRYONAL FACTORS AS ANTIINFECTIVE AGENTS	2/97-1/00	844,000
------------	---	-----------	---------

HEREDITARY DISEASE FOUNDATION

DR. SHERMAN	ROLE OF STRESS KINASE & HSPTS IN HUNTINGTON-INDUCED APOPTOSIS	2/99-1/01	111,000
DR. SHERMAN	SCREEN FOR COMPOUNDS THAT PREVENT AGGREGATION AND TOXICITY OF POLYQ CONTAINING POLYPEPTIDES USING YEAST	4/00-3/01	58,000*

MARCH OF DIMES

DR. COLUCCIO	MECHANOCHEMICAL PROPERTIES OF MAMMALIAN MYOSIN I'S	6/98-5/00	118,000
DR. DOMINGUEZ	STRUCTURAL BIOLOGY OF CALDESMON - BASED THIN FILAMENT REGULATION	2/00-1/02	100,000*

THE MEDICAL FOUNDATION-CHARLES A. KING TRUST

DR. YAGLOM (DR. SHERMAN)	THE ROLE OF HSP 72 IN REGULATION OF STRESS - KINASES	9/99-8/01	56,000*
-----------------------------	--	-----------	---------

THE MEDICAL FOUNDATION-HARCOURT GENERAL CHARITABLE FOUNDATION, INC.

DR. TOKER	THE ROLE OF PROTEIN KINASE C IN INTEGRIN-MEDIATED TUMOR INVASION	7/98-6/00	100,000
-----------	--	-----------	---------

SPONSORED RESEARCH

DR. PAULUS	PHARMING TECHNOLOGIES BV	1/99-12/00	202,000
------------	--------------------------	------------	---------

NIH FELLOWSHIPS AND CONFERENCE AWARDS

DR. LEINWEBER (DR. MORGAN)	FELLOWSHIP	7/98-6/01	81,000
DR. WANG	SMOOTH MUSCLE CELLS: STRUCTURE, MOTILITY & SIGNALING	4/99-4/00	15,000

*NEW GRANTS IN FISCAL 2000

STATEMENTS OF FINANCIAL POSITION

JUNE 30, 2000 AND 1999

ASSETS:	2000	1999
CASH	\$ 491,001	\$ 414,426
GRANTS RECEIVABLE	5,648,808	4,139,194
UNCONDITIONAL PROMISES TO GIVE	355,802	13,374
INVESTMENTS	18,039,094	12,698,221
PREPAYMENTS, DEPOSITS AND OTHER RECEIVABLES	190,397	100,008
TRUSTEE-HELD FUNDS	1,211,332	17,727,138
CONSTRUCTION-IN-PROGRESS	-	4,226,847
CAPITALIZED INTEREST	367,371	75,607
PROPERTY AND EQUIPMENT	16,799,971	1,375,023
DEFERRED COMPENSATION INVESTMENTS	<u>2,869,215</u>	<u>2,424,140</u>
TOTAL ASSETS	<u>\$45,972,991</u>	<u>\$43,193,978</u>
LIABILITIES AND NET ASSETS:		
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	\$ 999,473	\$ 651,438
ACCRUED INTEREST EXPENSE	393,628	128,646
DEFERRED INCOME	5,526,557	4,150,406
DEFERRED COMPENSATION PAYABLE	2,869,215	2,424,140
BONDS PAYABLE	<u>17,000,000</u>	<u>17,000,000</u>
TOTAL LIABILITIES	<u>26,788,873</u>	<u>24,354,630</u>
NET ASSETS:		
UNRESTRICTED	18,279,695	17,988,968
TEMPORARILY RESTRICTED	259,522	352,414
PERMANENTLY RESTRICTED	<u>644,901</u>	<u>497,966</u>
TOTAL NET ASSETS	<u>19,184,118</u>	<u>18,839,348</u>
 TOTAL LIABILITIES AND NET ASSETS	 <u>\$45,972,991</u>	 <u>\$43,193,978</u>

COPIES OF OUR COMPLETE, AUDITED FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST FROM THE CHIEF FINANCIAL OFFICER, BOSTON BIOMEDICAL RESEARCH INSTITUTE.

STATEMENTS OF ACTIVITIES

FOR THE YEARS ENDED JUNE 30, 2000 AND 1999

CHANGES IN UNRESTRICTED NET ASSETS:	2000	1999
REVENUES:		
GRANTS AND CONTRACTS	\$6,690,734	\$6,266,489
CONTRIBUTIONS	684,879	439,511
INVESTMENT INCOME	1,685,090	931,412
OTHER INCOME INCLUDING LICENSING FEES	14,273	22,032
TOTAL UNRESTRICTED REVENUES	<u>9,074,976</u>	<u>7,659,444</u>
NET ASSETS RELEASED FROM RESTRICTIONS	132,237	39,780
TOTAL UNRESTRICTED SUPPORT	<u>9,207,213</u>	<u>7,699,224</u>
EXPENSES:		
SALARIES AND BENEFITS	5,005,396	4,684,666
GENERAL SUPPORT AND SERVICES	1,733,856	1,374,735
OCCUPANCY COSTS	1,545,065	875,272
DEPRECIATION	571,272	355,837
FUND RAISING	60,897	89,719
TOTAL EXPENSES	<u>8,916,486</u>	<u>7,380,229</u>
INCREASE IN UNRESTRICTED NET ASSETS BEFORE EXTRAORDINARY GAIN	290,727	318,995
EXTRAORDINARY GAIN ON SALE OF LEASEHOLD	<u>-</u>	<u>7,560,366</u>
INCREASE IN UNRESTRICTED NET ASSETS	<u>290,727</u>	<u>7,879,361</u>
CHANGES IN TEMPORARILY RESTRICTED NET ASSETS:		
CONTRIBUTIONS	-	2,310
INVESTMENT INCOME	39,345	36,168
NET ASSETS RELEASED FROM RESTRICTIONS	<u>(132,237)</u>	<u>(39,780)</u>
DECREASE IN TEMPORARILY RESTRICTED NET ASSETS	<u>(92,892)</u>	<u>(1,302)</u>
CHANGES IN PERMANENTLY RESTRICTED NET ASSETS:		
CONTRIBUTIONS	100,000	-
INVESTMENT INCOME	<u>46,935</u>	<u>29,525</u>
INCREASE IN PERMANENTLY RESTRICTED NET ASSETS	<u>146,935</u>	<u>29,525</u>
INCREASE IN NET ASSETS	344,770	7,907,584
NET ASSETS AT BEGINNING OF YEAR	<u>18,839,348</u>	<u>10,931,764</u>
NET ASSETS AT END OF YEAR	<u><u>\$19,184,118</u></u>	<u><u>\$18,839,348</u></u>

STAFF

DIRECTOR

KATHLEEN G. MORGAN, PH.D.

DEPUTY DIRECTOR

HENRY PAULUS, PH.D.

SENIOR SCIENTISTS

JOHN A. BADWEY, PH.D.

LYNNE M. COLUCCIO, PH.D.

JOHN GERGELY, M.D., PH.D.,
D.SC.M.(HON.)

PHILIP J. GRACEFFA, PH.D.

NORIAKI IKEMOTO, PH.D.

PAUL LEAVIS, PH.D.

SHERWIN S. LEHRER, PH.D.

RENNE C. LU, PH.D.

KATHLEEN G. MORGAN, PH.D.

HENRY PAULUS, PH.D.

VICTOR A. RASO, PH.D.

NILIMA SARKAR, PH.D.

WALTER F. STAFFORD, III, PH.D.

TERENCE TAO, PH.D.

CHIH-LUEH ALBERT WANG, PH.D.

HARTMUT WOHLRAB, PH.D.

PRINCIPAL SCIENTISTS

ZENON GRABAREK, PH.D.

MICHAEL SHERMAN, PH.D.

ALEX TOKER, PH.D.

STAFF SCIENTISTS

ANDREW BOHM, PH.D.

ROBERTO DOMINGUEZ, PH.D.

PETER ERHARDT, PH.D.

STEEN HANSEN, PH.D.

CELIA J. HARRISON, PH.D.

JANET SMITH, PH.D.

SENIOR RESEARCH ASSOCIATES

ROQUE EL-HAYEK, M.D.

VLADIMIR GABAI, PH.D.

JONATHAN GOLDBERG, PH.D.

WILLIAM C. HATCH, PH.D.

KNUT LANGSETMO, PH.D.

YIN LUO, PH.D.

KATSUHIKO MABUCHI, PH.D.

RESEARCH ASSOCIATES

GONG-JIE CAO, PH.D.

SHU-QIN JIANG, PH.D.

FELLOWS

CORRADO BACCHIOCCHI, PH.D.

JOEL BARD, PH.D.

YAO DONG CHEN, PH.D.

YOUNG JIN CHOI, PH.D.

CHESTER DRUM, PH.D.

JUDITH GALLANT, PH.D.

JAYA PAL GANGOPADHYAY, PH.D.

SAMUDRA S. GANGOPADHYAY, PH.D.

NINA GOLITSINA, PH.D.

AMANDA HAEFELE, B.S.

HYUN DONG JE, PH.D.

JOLANTA KORDOWSKA, PH.D.

YOUNG-HO LEE, D.V.M., PH.D.

BARBARA LEINWEBER, PH.D.

LIAN-SHENG LI, M.D.

JIAN PING LIAN, PH.D.

GRETCHEN MEINKE, PH.D.

ANATOLI MERIIN, PH.D.

SANJAY MISHRA, PH.D.

PAUL MORGAN, PH.D.

KAORI SHINGLEDECKER, B.A.

MOHAMMED TERRAK, PH.D.

JOSEPH TOTH, PH.D.

CARLOS WITTE-HOFFMANN, M.D.

GUANMING WU, PH.D.

JULIA YAGLOM, PH.D.

GIAN ZHAN, PH.D.

XIAOQIAN ZHANG, PH.D.

EMERITUS SCIENTISTS

PETER S. COLEMAN, PH.D.

PETER F. DAVISON, PH.D.

JEN-SHIANG HONG, PH.D.

SAROJ JOSHI, PH.D.

D. RAO SANADI, PH.D.

FRANK SRETER, M.D., D.V.M., PH.D.

ADJUNCT SCIENTISTS

LEONARD ADAM, PH.D.

MICHAEL GEEVES, PH.D.

JAMES S. HUSTON, PH.D.

SATYAPRIYA SARKAR, PH.D.

BBRI SCHOLARS

WILLIAM C. HATCH, PH.D.

TAKESHI YAMAMOTO, M.D., PH.D.

RESEARCH ASSISTANTS

ADELAIDA D. CARLOS, B.S.

VITTORIA CENNI, B.S.

WENDY CHAPLIS, B.S.

SARAH DESJARDINS, B.S.

TANYA FREEDMAN, B.S.

CYNTHIA GALLANT, B.A.

PAULA F. GEARY, B.A.

AMY GELINAS, B.S.

BANG-JIAN GONG, M.B.

ELIZABETH GOWELL, B.S.

LAUREN GRAHAM, B.A.

HONGQUI GUO, M.S.

MARK R. HARRIES, B.A.

JESSICA JAIME, B.S.

CHRISTINE KEARNEY, B.S.

BING LI, M.B.

ZHAOJIANG LU, B.S.

YASUKO MABUCHI, M.S.

LUDOVIC OTTERBEIN, B.S.

MARIE-CLAIRE OVERGAAG, B.S.

GINA M. PAGANI, B.S.

LAKSHMI A. PALECANDA, B.S.

JESSICA PORTER, B.A.

SUJANA REDDY, B.S.

SOPHIA RITS-VOLLOCH, M.S.

ALESSANDRA SIRRI, B.S.

ALEX SUSHAN, B.S.

JING Y. TAN, M.D.

JENIFER TETRAULT, B.A.

GUANG YANG, M.S.

RONG ZHAO, B.S.

VISITING SCIENTISTS

WILLIAM E. BUTLER, M.D.

PAUL DURDA, PH.D.

JAMES S. HUSTON, PH.D.

NARUTO MATSUDA, M.D., PH.D.

UY DONG SOHN, PH.D.

MICHAEL TAGGART, PH.D.

STUDENTS

TODD ASHWORTH

ROMAN BELENKIY

KELLY A. BETHONEY

OSCAR RICHARD CARLOS

MICHAEL CARUSO

MELISSA GOODWILLIE

CHRISTOPHER LEE

BELINDA LEW, B.S.

MIMOZA MEHOLLI

KENNETH MILLS, B.S.

JOHN RODRIGUEZ

ANA CHRISTINA URBIN-REYES

ADMINISTRATION

THOMAS J. MCQUAID, C.P.A.

CHIEF FINANCIAL AND

ADMINISTRATIVE OFFICER

PATRICIA BROUILLETTE

HUMAN RESOURCES MANAGER

VIRGINIA CAHILL

FINANCIAL ASSISTANT

HELENE CLINTON

FINANCIAL ASSISTANT

COMPUTER SERVICES

WALTER F. STAFFORD, III, PH.D.

DIR. OF COMPUTER SERVICES

GARY HENRY

COMPUTER SERVICES TECHNICIAN

DEVELOPMENT & PUBLIC AFFAIRS

SIMON D.J. WELSBY

DIRECTOR OF DEVELOPMENT &

PUBLIC AFFAIRS

VIRGINIA M. SULLIVAN

CAMPAIGN MANAGER

KATHLEEN MACKINNON

DEVELOPMENT & PUBLIC AFFAIRS

COORDINATOR

FACILITIES

ROY E. MARVEL, MANAGER

ALAN SMITH, IN VIVO FACILITY MANAGER

YONIS DEL CARMEN AYALA

IN VIVO FACILITY ASSISTANT

JOHN COCHRANE, CARPENTER/SHIPPING

DAVID CARMICHAEL, ELECTRICIAN

ANGEL RIVERA, PLANT MECHANIC

DEBORAH SCIACCA, RECEPTIONIST

ADMINISTRATIVE ASSISTANTS

MARY CAULFIELD

MARILYN DEMONT

ANGELA DIPERRI

HELGA ISHIZAKA

DOROTHY SYRIGOS

HOUSEKEEPING


MARIA BOZZELLA

CONSTANCE GIANGREGORIO

NELIS PEREZ

JIAN QING YANG

EDITORS: JENNIFER LISK, KATHLEEN MORGAN, HENRY PAULUS, VIRGINIA SULLIVAN, SIMON WELSBY
CONTRIBUTORS: PETER ERHARDT, STEEN HANSEN
ARCHITECTURAL PHOTOGRAPHY: GREG PREMROU
DESIGN: PERUGI.COM



BOSTON BIOMEDICAL RESEARCH INSTITUTE
64 GROVE STREET
WATERTOWN, MA 02472 USA
TEL: 617-658-7700 FAX: 617-972-1760
<http://www.bbri.org>